G6PD deficiency
| G6PD deficiency | |
|---|---|
| Term | G6PD deficiency |
| Short definition | G-CSF - A drug used under the brand names Neupogen, Zarxio, and Nivestym to treat neutropenia (a below-average white blood cell count), prevent infection, and prepare the blood for the collection of certain types of blood cells and under the brand name Granix for the treatment of neutropenia. G-CSF is used in patients with certain types of cancer and neutropenia caused by certain types of chemotherapy and in patients with severe chronic neutropenia not caused by cancer treatment. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
G6PD deficiency - (pronounced) (. . . deh-FIH-avoid-see) An inherited disorder in which a person does not have enough of an enzyme called G6PD, which helps red blood cells work like they should. In G6PD deficiency, red blood cells break down when the body is exposed to infection, severe stress, or certain drugs, chemicals, or foods. This can lead to a condition called hemolytic anemia. This disorder is most common in African American men and in Middle Eastern or Mediterranean men. Also called glucose-6-phosphate dehydrogenase deficiency
External links
- Medical encyclopedia article on G6PD deficiency
- Wikipedia's article - G6PD deficiency
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski